Futura Medical PLC’s (LON:FUR) James Barder talks to Proactive London’s Katie Pilbeam about the highlights in their half-year report which includes the latest on MED3000 - a topical treatment for Erectile Dysfunction.
Proceedings have begun for formal approval of the drug to be approved as a 'over the counter' medical device and clinically proven treatment for ED in Europe by an EU Notified Body¹.
Barder then goes on to talk about Futura's other products which include TPR100 – to treat inflammatory pain as well as CBD100 - Futura's formulation using Cannabidiol.
The balance sheet shows a £1.06 million net loss in the period (30 June 2019: net loss £4.46 million). While cash resources currently sit at £2.62 million.
Note
¹Notified Bodies are organisations designated by EU countries to oversee the approval of medical devices within the EU and the UK.
